Thr494

Site Information
TGtDkLMtGVIsPER SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 2861408

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	lung cancer ( 1 ) , non-small cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:	E.coli (bacterial) ( 3 ) , HeLa S3 (cervical) ( 2 ) , lung ( 1 )

Upstream Regulation
Putative in vivo kinases:	MELK (human) ( 3 )
Kinases, in vitro:	MELK (human) ( 4 )

References
1	Rikova K (2009) CST Curation Set: 7879; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
2	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info
3	Badouel C, et al. (2006) M-phase MELK activity is regulated by MPF and MAPK. Cell Cycle 5, 883-9 16628004 Curated Info
4	Beullens M, et al. (2005) Substrate specificity and activity regulation of protein kinase MELK. J Biol Chem 280, 40003-11 16216881 Curated Info